challenges with immunotherapy in aml: target antigen selection, t-cell exhaustion and more
Published 1 year ago • 226 plays • Length 2:15Download video MP4
Download video MP3
Similar videos
-
2:05
challenges with immunotherapy in aml: on-target, off-tumor toxicity
-
1:48
the challenges of choosing the right target antigen in aml compared to all
-
3:09
challenges with immunotherapy in all
-
1:12
key challenges in immunotherapy for aml
-
1:44
challenges in developing car-t therapy for aml
-
2:32
if remission rates are high in aml, why are many patients not cured? #aml
-
2:30
new leukemia treatment gives hope to cancer sufferers
-
5:09
what do you see as the future of aml treatments? #aml
-
1:07
challenges in treating aml
-
2:22
t-cell bispecifics in aml: ongoing challenges and future outlooks
-
2:23
an update on car-t therapy in aml: challenges & emerging strategies
-
1:18
an insight into the challenges in prolonging remission in aml
-
1:29
aml immunotherapy: patients need to be well informed
-
2:08
challenges with car-t therapy in aml & insights into if-better-gated car-t cells
-
6:38
unmet needs and key challenges in the treatment of all
-
1:35
an overview of the main challenges to prolonging remission in aml
-
2:27
challenges with managing the high rates of infections seen in patients with aml
-
0:48
an overview of challenges that remain in the treatment of patients with al amyloidosis
-
2:17
session highlights: practical aspects of immunotherapy in multiple myeloma
-
1:11
adoptive cellular therapy in aml: challenges and different approaches
-
1:18
determining complete remission in patients with aml
-
1:28
car-t therapy in aml: why has there been a lack of success?